Gedeon Richter says that if its European denosumab filing continues along its current trajectory, “there’s a high probability that we can launch on time and have a relatively short approval process, which gives hope that the denosumab launch taking place next year will be successful.”
Richter Eyeing 20%+ Margin On Denosumab As Part Of 2027 Profit Plans
Peak Sales For Prolia/Xgeva Biosimilar Tipped At €80m; US Filing ‘Not Yet Happened’
Gedeon Richter is feeling good about its plan to launch a biosimilar denosumab product in the EU in 2025, as it continued to slow down losses for its biopharma unit ahead of plans to swing to profitability later in the decade.
